Mumbai-based Shreya Life Sciences, set up in 2010, markets a wide range of pharmaceutical products and has presence in therapeutic segments such as cardiology, diabetology, anti-microbials, anti-tuberculosis, anti-osteoporotics, anti-malarials, gastrointestinals, pain management, gynaecology, paediatric care, infertility management and diabetes care. The company has a product portfolio comprising more than 200 products across various therapeutic segments.
The firm in 2002 launched operations in Russia, where it currently offers more than 31 prescription, over-the-counter (OTC) and generic products.
Apart from Russia, the company also has operations in Ukraine, Uzbekistan, Belarus and Kazakhstan in the region and globally in Africa, South America and South-east Asia.
Its Russian arm operates through major distributors which supply its products to more than 25,000 retail pharmacies (aptekas) across the country. In addition, its products are also distributed through the approved list of the Russian government’s Public Distribution System.
Now, Aurobindo Pharma Ltd is aiming to acquire the Russia business of Shreya Life Sciences. The deal is said to be valued between $80 million and $100 million.
A spokesperson for Shreya Life Sciences said, “We are not considering any sale of our Russian business. We have certain market authorization/registrations which are currently not bein
The Hyderabad-based Pharma has been one of the most acquisitive domestic pharma companies, already in a race to acquire a part of the European assets of Israeli generic drugmaker Teva Pharmaceutical Industries Ltd in a deal which, if completed, could be the biggest overseas acquisition by an Indian pharma company.
